Our team is experienced in providing a full range of counseling, litigation, and advocacy services on pharmaceutical pricing issues for our clients. We regularly provide advice, in-depth analyses, and internal training on calculating the various pricing metrics that are reported to federal agencies or that set price ceilings (e.g., AMP, Best Price, Section 340B, ASP, non-FAMP and federal ceiling price), and on related reporting and administrative requirements. We also represent clients in negotiating Federal Supply Schedule (FSS) contracts and advise on the price disclosure and reporting requirements associated with FSS contracts.
We also represent companies in connection with litigation, internal investigations, and government audits concerning pharmaceutical pricing issues and have frequently assisted manufacturers in conducting reviews to evaluate the adequacy of existing compliance policies and procedures in the pricing area. Our representation of an industry trade association on pricing and related legislative matters, combined with our work for a diverse range of individual companies, has given us a distinct, industry‑wide perspective of the pharmaceutical pricing landscape.
Major manufacturers and a leading industry trade association rely on us for advice on the intersection of state and federal fraud and abuse laws with developing government pricing and reimbursement issues. Our activities in this area include analyzing state and federal regulations, developing offensive and defensive pricing, coverage and reimbursement strategies, and government advocacy.